The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40.
Univest Financial Corporation
UVSP · Nasdaq · USD · Market cap $1.1B
Univest Financial Corporation operates as the bank holding company for Univest Bank and Trust Co.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price40.52 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $44.25 to $73.75, base estimate $47.00 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Univest Financial Corporation holds its Distribution at $40.52. The statistical read favours the sellers, held for 61 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 61 days |
| Price at the screen | $40.52 |
| Valuation | 12.27 trailing · 10.45 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.66 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: bank | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Univest Financial does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when UVSP's ethical verdict changes
Today UVSP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 14% discount to our $47.00 fair value.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 13.8% discount to the base estimate.
Third-party analyst targets: 3 covering, consensus Hold. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $47.00, with a range of $44.25 to $73.75, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsEveryday banking services hit our ethical wall
Picture a local branch handling mortgages and small business accounts for families and shops. Univest Financial delivers those services through its banking, wealth and insurance arms, yet we pass without hesitation. The ethical screen rules out any exposure to banks on principle, regardless of the 12% revenue growth or 30% profit margin on offer.
Forward earnings sit at 11.8 times with a 10% return on equity that offers little distinction. The current price of 44.58 dollars sits almost exactly at our fair value of 45 dollars, leaving no margin of safety, and three analysts rate the shares a hold with a 43 dollar median target.
Risk sits in the combination of modest returns, a cyclical sector and zero ethical clearance. The screen exists for exactly these cases. Analysis, not advice.
| Forward P/E | 10.4xreasonably valued |
| Trailing P/E | 12.3xreasonably valued |
| EPS, trailing | 3.35 |
| EPS, forward | 3.93 |
| Revenue growth | -2.1%revenue is shrinking |
| Profit margin | 28.8%healthy profit margins |
| Return on equity | 10.0%a modest return on shareholder capital |
| Dividend yield | 2.34% |
| Beta | 0.66steadier than the market |
| Short interest, float | 0.04% |
| 52-week range | 28.20 - 45.46 |
| Market cap | $1.1B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeUVSP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 44%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (3 analysts) rates it none, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- What Univest Financial (UVSP)'s Loan Charge Offs Mean For Shareholders Yahoo Finance · 16d ago
- Univest Financial (UVSP) Stock Looks Discounted Following Its 138% Run Yahoo Finance · 16d ago
- Univest Corporation of Pennsylvania Q3 Earnings Call Highlights Yahoo Finance · 17d ago
- Univest (UVSP) Q3 2026 Earnings Call Transcript Yahoo Finance · 18d ago
- Univest Financial Corporation Q3 2026 Earnings Call Summary Yahoo Finance · 18d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $38.27 | +9.2% | · | $1,092 | +9.2% |
| 2 months | $36.89 | +13.3% | $0.23 | $1,139 | +13.9% |
| 3 months | $32.57 | +28.3% | $0.23 | $1,290 | +29.0% |
| 6 months | $35.04 | +19.3% | $0.45 | $1,206 | +20.6% |
| 1 year | $28.96 | +44.3% | $0.89 | $1,474 | +47.4% |
| 2 years | $19.81 | +110.9% | $1.74 | $2,197 | +119.7% |
| 3 years | $18.28 | +128.6% | $2.58 | $2,427 | +142.7% |
| 5 years | $23.78 | +75.7% | $4.23 | $1,935 | +93.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever UVSP does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.